Literature DB >> 12477778

Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets.

D W Hommes1, M P Peppelenbosch, S J H van Deventer.   

Abstract

Over the last decade important advances have been made in our understanding of the molecular events underlying cellular responses to extracellular signals. Increased understanding of signal transduction mechanisms and gene regulation involved in immune responses has created opportunities for the discovery of novel therapeutic compounds useful in treating inflammatory disorders. One of the best studied signalling routes is the mitogen activated protein (MAP) kinase signal transduction pathway which plays a crucial role in many aspects of immune mediated inflammatory responses. Here, our current understanding of the MAP kinase pathway is reviewed, as well as recent advances in the design of novel agents that are able to modulate the activity of these signalling cascades.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477778      PMCID: PMC1773518          DOI: 10.1136/gut.52.1.144

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  71 in total

Review 1.  Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.

Authors:  Roman Herrera; Judith S Sebolt-Leopold
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

Review 2.  NFAT signaling: choreographing the social lives of cells.

Authors:  Gerald R Crabtree; Eric N Olson
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 3.  An invitation to T and more: notch signaling in lymphopoiesis.

Authors:  David Allman; Jennifer A Punt; David J Izon; Jon C Aster; Warren S Pear
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

4.  Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.

Authors:  A C Maroney; J P Finn; T J Connors; J T Durkin; T Angeles; G Gessner; Z Xu; S L Meyer; M J Savage; L A Greene; R W Scott; J L Vaught
Journal:  J Biol Chem       Date:  2001-04-26       Impact factor: 5.157

5.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Authors:  Z Han; D L Boyle; L Chang; B Bennett; M Karin; L Yang; A M Manning; G S Firestein
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

6.  Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis.

Authors:  T ten Hove; B van den Blink; I Pronk; P Drillenburg; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

7.  Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects.

Authors:  Tatsuro Mori; Xiaoying Wang; Jae-Chang Jung; Toshihisa Sumii; Aneesh B Singhal; M Elizabeth Fini; C Edward Dixon; Alessandro Alessandrini; Eng H Lo
Journal:  J Cereb Blood Flow Metab       Date:  2002-04       Impact factor: 6.200

8.  Role of ERK and p38 mitogen-activated protein kinase cascades in gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.

Authors:  B L Slomiany; A Slomiany
Journal:  IUBMB Life       Date:  2001-05       Impact factor: 3.885

9.  p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease.

Authors:  Georg H Waetzig; Dirk Seegert; Philip Rosenstiel; Susanna Nikolaus; Stefan Schreiber
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

10.  Stress kinase inhibition modulates acute experimental pancreatitis.

Authors:  F Fleischer; R Dabew; B Göke; A C Wagner
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

View more
  118 in total

1.  Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway.

Authors:  Wen-jing Cui; Yi Liu; Xiao-lei Zhou; Feng-ze Wang; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2010-05-10       Impact factor: 6.150

2.  Flavonoids in modulation of cell survival signalling pathways.

Authors:  Mohammad Lukman Mansuri; Priyanka Parihar; Isha Solanki; Mordhwaj S Parihar
Journal:  Genes Nutr       Date:  2014-03-30       Impact factor: 5.523

Review 3.  A Review on Potential Footprints of Ferulic Acid for Treatment of Neurological Disorders.

Authors:  Surabhi Thapliyal; Tanveer Singh; Shailendra Handu; Manisha Bisht; Puja Kumari; Priyanka Arya; Pallavi Srivastava; Ravi Gandham
Journal:  Neurochem Res       Date:  2021-02-05       Impact factor: 3.996

4.  A computational framework for the topological analysis and targeted disruption of signal transduction networks.

Authors:  Madhukar S Dasika; Anthony Burgard; Costas D Maranas
Journal:  Biophys J       Date:  2006-04-14       Impact factor: 4.033

Review 5.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

6.  Opposing effects of proteasomes and lysosomes on LIFR: modulation by TNF.

Authors:  Chuanhui Yu; Abba J Kastin; Hong Tu; Weihong Pan
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

7.  Runt-related Transcription Factor 1 (RUNX1) Binds to p50 in Macrophages and Enhances TLR4-triggered Inflammation and Septic Shock.

Authors:  Mao-Cai Luo; Si-Yuan Zhou; Dan-Ying Feng; Jun Xiao; Wei-Yun Li; Chun-Di Xu; Hong-Yan Wang; Tong Zhou
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

8.  Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action.

Authors:  Hong Sun; Juan Ren; Qing Zhu; Fan-Zhong Kong; Lei Wu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 9.  Key role of ERK pathway signaling in lupus.

Authors:  Gabriela Gorelik; Bruce Richardson
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 10.  Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.

Authors:  J Kay Noel; Sheila Crean; Janet E Claflin; Gayatri Ranganathan; Heather Linz; Michael Lahn
Journal:  Med Oncol       Date:  2008-01-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.